Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma

• Published in: Theranostics Vol. 10; no. 9; pp. 4116 - 4133
• Main Authors: Kryza, Thomas, Khan, Tashbib, Puttick, Simon, Li, Chao, Sokolowski, Kamil A, Tse, Brian Wc, Cuda, Tahleesa, Lyons, Nicholas, Gough, Madeline, Yin, Julia, Parkin, Ashleigh, Deryugina, Elena I, Quigley, James P, Law, Ruby H P, Whisstock, James C, Riddell, Andrew D, Barbour, Andrew P, Wyld, David K, Thomas, Paul A, Rose, Stephen, Snell, Cameron E, Pajic, Marina, He, Yaowu, Hooper, John D
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01.01.2020; Ivyspring International Publisher
• Subjects: Animals; Antibodies; Antigens, Neoplasm - metabolism; Biomarkers, Tumor - metabolism; Breast cancer; Cancer therapies; Carcinoma, Pancreatic Ductal - metabolism; Carcinoma, Pancreatic Ductal - therapy; Cell Adhesion Molecules - metabolism; Cell Line, Tumor; Consortia; Disease Progression; Gene Expression Regulation, Neoplastic; Genomes; Humans; Laboratories; Metastasis; Mice; Pancreatic cancer; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - therapy; Patients; Precision Medicine; Prostate cancer; Proteolysis; Research Paper; Signal transduction; Tumors; monoclonal-antibody; PET-CT; theranostics; pancreatic cancer; CDCP1

: CUB domain-containing protein 1 (CDCP1) is a cell surface receptor regulating key signalling pathways in malignant cells. CDCP1 has been proposed as a molecular target to abrogate oncogenic signalling pathways and specifically deliver anti-cancer agents to tumors. However, the development of CDCP1...